10 consecutive boards Shuangcheng Medicine: There is uncertainty whether the major asset restructuring can be successfully implemented.

Jinshi Data News on September 26th, Shuangcheng Pharmaceutical Industry issued a public announcement of abnormal Fluctuation in stock trading and risk reminders, the company followed and verified the relevant situations, and there is no need to correct or supplement the disclosed information in the previous period. No recent public media reports that may have had a significant impact on the company’s stock trading price have been found. The company is planning a major asset restructuring, and the audit and evaluation work of this transaction has not been completed. The specific transaction price has not been determined, and there is uncertainty about whether the implementation can be successful in the end.